Comments
Shares of Alembic Pharmaceuticals will remain in focus, as the company on Tuesday said it has received final approval from the US Food & Drug Administration to market Travoprost ophthalmic solution, used in the treatment of glaucoma.
Alembic said its product is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Alembic now has 110 abbreviated new drug application approvals from the USFDA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.